Dietary Supplements for COVID-19

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blind, placebo controlled, phase III randomized controlled trial evaluating the effects of the dietary supplements vitamin C, vitamin D, vitamin K, and zinc versus placebo on the overall health, symptom severity, and symptom duration of outpatients diagnosed with SARS-CoV-2.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Canadian College of Naturopathic Medicine
• Collaborators: New Roots Herbal; Ottawa Hospital Research Institute; Vitazan Professional
• Treatments: Cholecalciferol; Vitamin D; Vitamin K; Vitamin K 2; Vitamins

Criteria

Inclusion Criteria:

1. Adults (≥18) who test positive for SARS-CoV-2 in an outpatient setting

2. Access to internet

Exclusion Criteria:

1. Symptom onset greater than 4 days prior to enrolment

2. Supplementing regularly with >500 mg vitamin C, >1000 units vitamin D, >120 mcg vitamin K (any form), or >15 mg zinc taken daily within the past month

3. Currently taking warfarin or an equivalent vitamin K antagonist anticoagulant

4. End stage chronic kidney disease

5. History of calcium oxalate kidney stones

6. Active granulomatosis (sarcoidosis, tuberculosis, lymphoma)

7. Known hypercalcemia or hypervitaminosis D

8. Currently taking either of the following antibiotics: cephalexin, tetracyclines

9. Participating in an investigational study or participation in an investigational study within the past 30 days

10. Any reason which, under the discretion of the qualified investigator or delegate, would preclude the patient from participating.